How long can Axitinib prolong life in advanced kidney cancer?

Axitinib (Axitinib) is a targeted therapy drug mainly used to treat advanced renal cell carcinoma (RCC). In the treatment of advanced renal cell carcinoma, axitinib inhibits the vascular endothelial growth factor receptor (VEGFR) and interferes with the blood supply of the tumor, thereby slowing down tumor growth and spread.

The use of axitinib has shown a positive impact on patient survival in clinical trials. However, the specific survival time extension varies depending on factors such as individual differences, disease severity, and treatment response.

In some clinical trials, patients treated with axitinib generally showed longer progression-free survival (progression-free survival, PFS) and overall survival (overall survival, OS) compared with the control group. This means axitinib may be able to prolong the time patients can survive without disease progression or in the face of advanced cancer.

However, it is important to note that the effect of survival extension may differ for each patient. Some patients may show a more robust positive response to treatment with axitinib, while others may experience varying degrees of effects from treatment. In addition, axitinib is not a curative drug. It is mainly used to relieve symptoms, prolong survival, and improve quality of life.

Axitinib has been launched in China and has been included in medical insurance. Patients can purchase it domestically. The price of 5mg*28 tablets is about 5,000 to 6,000 yuan. For specific prices, please consult the local hospital pharmacy. There are original and generic axitinib drugs abroad. The original drug is Pfizer's original drug, and the price is about 6,000 yuan; the generic drugs are mainly Bangladeshi generics and Indian generics. The price of Bangladeshi generics in 5mg*60 tablets is more than 1,000 yuan, and the price of Indian generics is around a few hundred yuan. The ingredients of original drugs and generic drugs are basically the same.